Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Colorectal Neoplasms 9Pancreatic Neoplasms 6Ovarian Neoplasms 5Sarcoma 4Neuroblastoma 4Liver Neoplasms 4Wilms Tumor 3Somatostatinoma 3Rectal Neoplasms 3Osteosarcoma 3Neuroendocrine Tumors 3Neuroectodermal Tumors, Primitive, Peripheral 3Neoplasms 3Medulloblastoma 3Gastrointestinal Stromal Tumors 3Esophageal Neoplasms 3Astrocytoma 3Zollinger-Ellison Syndrome 2Vipoma 2Testicular Neoplasms 2Teratoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Pheochromocytoma 2Ovarian Germ Cell Cancer 2Optic Nerve Glioma 2Oligodendroglioma 2Neoplasm Metastasis 2Melanoma 2

Interventions

veliparib 1ribociclib 1cabozantinib 1X-Rays 1Temozolomide 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Chromogranin A 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non functioning pancreatic endocrine tumor × Temozolomide × Gastrointestinal × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡